Increased risk for acute myeloid leukaemia in individuals with glutathione <i>S</i>‐transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects

Abstract

Our observation of a 4.7-fold (95% CI: 2.1-11.0) and 2.3-fold (95% CI: 1.0-5.2) increased risk associated with the GSTM1 and GSTT1 null genotypes, respectively, and a 6.6-fold (95% CI: 2.4-7.9) increased risk associated with the combined null genotype presents preliminary evidence that the inherited absence of this carcinogen detoxification pathway may be an important determinant of AML.